초록 ▼

The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. The tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as those occur in cancerous cells. The

The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. The tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as those occur in cancerous cells. The methods provided herein include administering to the mammal, an effective amount of a composition that alters the activity of transition molecules within a cell. Transition molecules are shown to be comprised of hyaladherins, hyaluronans and associated molecules that regulate the transitional phenotype.

대표청구항 ▼

1. An isolated polypeptide of less than 60 amino acid residues comprising at least one amino acid sequence BX7B motif consisting of amino acid sequence of SEQ ID NO:28 which binds hyaluronic acid, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 27,

1. An isolated polypeptide of less than 60 amino acid residues comprising at least one amino acid sequence BX7B motif consisting of amino acid sequence of SEQ ID NO:28 which binds hyaluronic acid, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 69 and SEQ ID NO: 71.2. A composition comprising at least one polypeptide according to claim 1.3. The polypeptide of claim 1 which is less than 50 amino acid residues.4. The polypeptide of claim 1 which is less than 40 amino acid residues.5. The polypeptide of claim 1 which is less than 30 amino acid residues.6. The polypeptide of claim 1 which is less than 20 amino acid residues.7. The polypeptide of claim 1 which is an amino acid sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 51, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 69 and SEQ ID NO: 71.8. The composition of claim 2 which comprises a pharmaceutically or physiologically acceptable carrier, excipient or diluent.9. The composition of claim 2 which is formulated for administration by a route selected from the group consisting of systemic, oral, rectal, intravenous, intramuscular, subcutaneous, ocular and topical.10. The composition of claim 2 wherein the polypeptide is delivered at a dose ranging from 1 ng/kg to 80 mg/kg.11. A method of treating a condition selected from the group consisting of tissue disorders associated with a response-to-injury process, proliferative disorders and diseases and inflammatory disorders and diseases comprising administering to a subject in need thereof at least one polypeptide according to any of claims 1 or 3-7.12. A method of treating a condition selected from the group consisting of tissue disorders associated with a response-to-injury process, proliferative disorders and diseases and inflammatory disorders and diseases comprising administering to a subject in need thereof at least one composition according to any of claims 2 or 8-10.13. The method of claim 11 wherein the condition is selected from the group consisting of multiple sclerosis, diabetes, obesity, wounds and restenosis.14. The method of claim 12 wherein the condition is selected from the group consisting of multiple sclerosis, diabetes, obesity, wounds and restenosis.